Australia's most trusted
source of pharma news
Wednesday, 20 August 2025
Posted 20 August 2025 PM
Novo Nordisk's Ozempic has become the first GLP-1 receptor agonist drug approved for patients with chronic kidney disease (CKD) in Australia.
Ozempic, which has gained popularity in recent years for its weight loss benefits, was until recently only registered on the ARTG for certain patients with type 2 diabetes.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.